IRB failings compromise trial safety and validity; OHRP

By Nick Taylor

- Last updated on GMT

Related tags: Institutional review board, Irb

Numerous members of IRBs have conflicts of interest, lack the necessary expertise and fail to follow HHS regulations, according to the OHRP.

The findings were published by the Office for Human Research Protections (OHRP) in a review of institutional review board (IRB) activities.

In the review, which is based on compliance oversight determination letters from the past few years, the OHRP details numerous IRB failings that could have an impact on the safety and validity of clinical trials.

One of the significant findings is that IRB members voted on protocols on which they were also investigators, which contravenes US Department of Health and Human Services (HHS) regulations.

In addition to these conflicts of interest the composition of some IRBs is flawed, with the members collectively lacking the background and experience required by the HHS.

Race, gender, cultural backgrounds and sensitivity to issues such as community attitudes, in relation to the locality of the research, must all be considered when forming an IRB.

As well as failing to comply with this some IRBs have lacked a member who is not associated with the institution the board is reviewing.

Further composition errors were made by not including a non-scientist in expedited review procedures and failing to have a prisoner or suitable representative present when reviewing trials on inmates.

These oversights may be attributed to the IRB chairperson and members lack of understanding of the HHS regulations. Deviation from these regulations is raised in the review, with particular reference to not comprehending the regulations that are in place to safeguard the rights and welfare of human subjects.

However, the OHRP also puts the difficulties facing IRBs in context, saying that the boards are under resourced. In particular they lack sufficient meeting space and staff to perform their review and recordkeeping duties.

The complete OHRP review can be found here​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars